The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nelson, D. J.
Right arrow Articles by Robinson, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, D. J.
Right arrow Articles by Robinson, B.
The Journal of Immunology, 2001, 166: 5557-5566.
Copyright © 2001 by The American Association of Immunologists

Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective "Arming" of Tumor Antigen-Specific CTL1

Delia J. Nelson2,*,{dagger}, Sutapa Mukherjee*, Christine Bundell*, Scott Fisher*, Deborah van Hagen* and Bruce Robinson2,*,{dagger}

* Department of Medicine, University of Western Australia, Nedlands, Queen Elizabeth II Medical Center, Perth, Western Australia, Australia; and {dagger} West Australian Institute for Medical Research, Queen Elizabeth II Medical Center, Perth, Western Australia, Australia

To determine whether APC function or "arming" of CTL for lytic function are the points at which Ags from a nonimmunogenic tumor fail to induce an effective immune response, we established a murine tumor model that expressed intracellular OVA and selected a clone (cOVA-9) that remained susceptible to lysis by specific CD8+ T cells throughout tumor growth. Viable cOVA-9 tumor cells grew in normal mice at a rate similar to the parental tumor, and vaccination with irradiated cOVA-9 cells did not induce protection against itself or the parental line, confirming its nonimmunogenic status. In vivo evaluation during tumor growth demonstrated persisting tumor Ag cross-presentation accompanied by the generation of potent, specific CTL which were detectable when tumors were barely palpable. Despite the presence of highly active CTL in the tumor-draining lymph nodes, there was no apparent lysis of tumor-associated APC. These data show that tumor-draining APC are not dysfunctional with regard to two crucial processes, in vivo tumor Ag cross-presentation and specific CTL arming, and that failure to prevent tumor growth is not in the induction phase, but in the effector phase and occurs within the tumor itself before the tumor matrix is established.




This article has been cited by other articles:


Home page
 Int ImmunolHome page
C. Jackaman, A. M. Lew, Y. Zhan, J. E. Allan, B. Koloska, P. T. Graham, B. W. S. Robinson, and D. J. Nelson
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site
Int. Immunol., September 29, 2008; (2008) dxn104v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. J. Currie, R. G. van der Most, S. A. Broomfield, A. C. Prosser, M. G. Tovey, and B. W. S. Robinson
Targeting the Effector Site with IFN-{alpha}{beta}-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors
J. Immunol., February 1, 2008; 180(3): 1535 - 1544.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Perez-Diez, N. T. Joncker, K. Choi, W. F. N. Chan, C. C. Anderson, O. Lantz, and P. Matzinger
CD4 cells can be more efficient at tumor rejection than CD8 cells
Blood, June 15, 2007; 109(12): 5346 - 5354.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. M. Hargadon, C. C. Brinkman, S. L. Sheasley-O'Neill, L. A. Nichols, T. N. J. Bullock, and V. H. Engelhard
Incomplete Differentiation of Antigen-Specific CD8 T Cells in Tumor-Draining Lymph Nodes
J. Immunol., November 1, 2006; 177(9): 6081 - 6090.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. T. Joncker, J. Helft, A. Jacquet, V. Premel, and O. Lantz
Intratumor CD4 T-cell accumulation requires stronger priming than for expansion and lymphokine secretion.
Cancer Res., May 15, 2006; 66(10): 5443 - 5451.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Liu, S. A. Caldwell, and S. I. Abrams
Immune Selection and Emergence of Aggressive Tumor Variants as Negative Consequences of Fas-Mediated Cytotoxicity and Altered IFN-{gamma}-Regulated Gene Expression
Cancer Res., May 15, 2005; 65(10): 4376 - 4388.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. R. Jenkinson, N. A. Williams, and D. J. Morgan
The Role of Intercellular Adhesion Molecule-1/LFA-1 Interactions in the Generation of Tumor-Specific CD8+ T Cell Responses
J. Immunol., March 15, 2005; 174(6): 3401 - 3407.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Hirano, K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D. B. Flies, J. S. Lau, G. Zhu, et al.
Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
Cancer Res., February 1, 2005; 65(3): 1089 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. C. Jackson, Y. F. Lau, T. Le, A. Suhrbier, G. Deliyannis, C. Cheers, C. Smith, W. Zeng, and L. E. Brown
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
PNAS, October 26, 2004; 101(43): 15440 - 15445.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Cuenca, F. Cheng, H. Wang, J. Brayer, P. Horna, L. Gu, H. Bien, I. M. Borrello, H. I. Levitsky, and E. M. Sotomayor
Extra-Lymphatic Solid Tumor Growth Is Not Immunologically Ignored and Results in Early Induction of Antigen-Specific T-Cell Anergy: Dominant Role of Cross-Tolerance to Tumor Antigens
Cancer Res., December 15, 2003; 63(24): 9007 - 9015.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Jackaman, C. S. Bundell, B. F. Kinnear, A. M. Smith, P. Filion, D. van Hagen, B. W. S. Robinson, and D. J. Nelson
IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2
J. Immunol., November 15, 2003; 171(10): 5051 - 5063.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. K. Nowak, R. A. Lake, A. L. Marzo, B. Scott, W. R. Heath, E. J. Collins, J. A. Frelinger, and B. W. S. Robinson
Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells
J. Immunol., May 15, 2003; 170(10): 4905 - 4913.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Schuler and T. Blankenstein
Cutting Edge: CD8+ Effector T Cells Reject Tumors by Direct Antigen Recognition but Indirect Action on Host Cells
J. Immunol., May 1, 2003; 170(9): 4427 - 4431.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
U. Blohm, E. Roth, K. Brommer, T. Dumrese, F. M. Rosenthal, and H. Pircher
Lack of Effector Cell Function and Altered Tetramer Binding of Tumor-Infiltrating Lymphocytes
J. Immunol., November 15, 2002; 169(10): 5522 - 5530.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Kammerer, D. Stober, P. Riedl, C. Oehninger, R. Schirmbeck, and J. Reimann
Noncovalent Association with Stress Protein Facilitates Cross-Priming of CD8+ T Cells to Tumor Cell Antigens by Dendritic Cells
J. Immunol., January 1, 2002; 168(1): 108 - 117.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.